Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2014
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Tegobuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 10 Oct 2011 According to the Clinical Trials Database record, status changed from recruiting to completed.
- 08 Jun 2011 New trial record